e-learning
resources
Munich 2014
Sunday, 07.09.2014
The assessment of comorbidities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Volatile organic compounds in exhaled breath of patients with COPD ± lung cancer and their correlation with FEV1-values
M. Westhoff, P. Litterst, H. Sommer, B. Bödecker, J. I. Baumbach (Hemer, Münster, Dortmund, Reutlingen, Germany)
Source:
International Congress 2014 – The assessment of comorbidities
Session:
The assessment of comorbidities
Session type:
Thematic Poster Session
Number:
987
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Westhoff, P. Litterst, H. Sommer, B. Bödecker, J. I. Baumbach (Hemer, Münster, Dortmund, Reutlingen, Germany). Volatile organic compounds in exhaled breath of patients with COPD ± lung cancer and their correlation with FEV1-values. Eur Respir J 2014; 44: Suppl. 58, 987
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
Differences in volatile organic compounds (VOC) determined in exhaled breath in two populations of lung cancer (LC): With and without COPD
Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer
Year: 2013
Using exhaled breath profiles in the discrimination between COPD, lung cancer and their co-morbidity
Source: International Congress 2015 – Developments in lung cancer diagnosis
Year: 2015
Volatile organic compounds in COPD: Is hexanal an inflammation biomarker?
Source: International Congress 2016 – The future of lung function is beginning now
Year: 2016
Volatile organic compounds of exhaled breath in lung cancer and lung inflammatory diseases
Source: Annual Congress 2013 –Epidemiology, screening and diagnosis of lung cancer
Year: 2013
Analysis of exhaled air for a rapid, sensible and specific diagnosis of COPD
Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease
Year: 2015
Exhaled particles from small airways in COPD patients – A pilot study
Source: International Congress 2014 – Monitoring airway diseases with lung function tests
Year: 2014
Metabolomic analysis of exhaled breath condensate in patients with asthma and COPD
Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases
Year: 2013
Exhaled breath condensate hydrogen peroxide in obstructive airways disease
Source: International Congress 2014 – Airway biomarkers
Year: 2014
Unbiased clustering of severe asthma patients based on exhaled breath profiles
Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease
Year: 2015
Double-tracer gas washout in stable asthma and COPD
Source: International Congress 2014 – Monitoring airway diseases with lung function tests
Year: 2014
The analysis of breath air by laser spectroscopy method for diagnosis of COPD
Source: International Congress 2014 – Airway biomarkers
Year: 2014
Breath volatile organic compound (VOC) COPD study at two DZL centers - Evaluation of site-specific VOC
Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease
Year: 2015
Monitoring exhaled carbon monoxide in COPD exacerbations
Source: International Congress 2014 – Airway biomarkers
Year: 2014
Changes in PH of exhaled breath condensate after specific inhalation challenge test, in patients with hypersensitivity pneumonitis
Source: International Congress 2014 – ILDs 3
Year: 2014
Volatile organic compounds in exhaled breath samples as potential biomarkers in early diagnosis of lung cancer – (Ege translational pulmonology research group [EgeTPAG])
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Exhaled breath condensate biomarkers in COPD
Source: Eur Respir J 2008; 32: 472-486
Year: 2008
Hydrogen sulfide (H
2
S) in sputum and serum as a novel biomarker of COPD
Source: International Congress 2014 – Systemic biomarkers for airway diseases
Year: 2014
Identification of exhaled volatile organic compounds (VOCs) associated with loss of asthma control
Source: International Congress 2016 – Assessing lower airway inflammation with different tools
Year: 2016
Analysis of semi-volatile organic compounds in exhaled breath condensate of patients with obstructive lung diseases
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
The impact of acute smoke exposure on selected biomarkers in exhaled breath condensate in COPD patients and healthy smokers
Source: International Congress 2016 – Molecular pathways of smoking-induced diseases
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept